Soins de première ligne pour populations vulnérables: peut-on prévenir et mieux soigner les comorbidités associées au VIH et au VPH?


Alexandra De Pokomandy

Institut de recherche du Centre universitaire de santé McGill


Domaine : santé des populations

Programme Chercheurs-boursiers cliniciens - Junior 2

Concours 2018-2019

Infection with HIV or with the human papillomavirus (HPV) increases the risk of cancer and other comorbidities. My research program includes 3 projects to prevent and better treat comorbidities associated with these infections.

The CHIWOS study is a cohort of 1,422 women living with HIV in Canada (British Columbia, Ontario and Quebec), conducted according to the principles of participatory research. The project questions the overall reproductive and sexual health of women and assesses whether the current service offer meets their needs. The study involves three questionnaires completed every 18 months.

Anal cancer is primarily caused by the persistence of infections by high-risk HPV types. The EVVA study (HPV, HIV and Anal Lesions) study measures the prevalence and natural evolution of HPV infections and precancerous anal lesions in women living with HIV over 2 years. The strengths of this study are the complete genotyping of detected cervical and anal HPV, cytology, and high-resolution anoscopy with biopsies (the only recognized diagnostic method) in all participants.

Men who have sex with men remain the population at higher risk of anal cancer. The LIMIT-HPV study is a randomized controlled trial in men (HIV-negative and positive) comparing a lubricant gel with carrageenan and a placebo, used for one year, to reduce prevalence and incidence of HPV in the anal canal.

This research program will generate new knowledge, will have a significant impact on the prevention of comorbidities related to HIV and HPV and will improve health care and overall quality of life of vulnerable populations.